Avandia’s Fate May Hang On How Advisory Cmte. Weighs Meta-Analyses Vs. Other Data
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA notes “considerable concern” about cardiovascular signal, while GSK points to positive epidemiologic data in the run-up to the July 30 committee meeting on the diabetes drug.